Search filters

List of works by Anna Maria Langkilde

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

scientific article published on 18 December 2020

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

scientific article published on 19 September 2019

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial

scientific article published on 05 July 2020

Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

scientific article published on 04 September 2020

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

scientific article published on 27 March 2020

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

scientific article published on 21 August 2020

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

scientific article published on 17 November 2019

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

scientific article published on 28 March 2020

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

scientific article published on 17 November 2019

Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF

scientific article published on 15 June 2020

The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics

scientific article published on 15 July 2019

Paulina is supported by:

About Paulina

Help